Origins of FL genes

Tier 1 FL genes

66 total

Gene Summary First FL study Other entities QC result
ACTB Tier 1 GE lohrDiscoveryPrioritizationSomatic2012a?,wienandGenomicAnalysesFlowsorted2019b?
ARID1A Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FE1 Krysiak et al 2,3,rossiCodingGenomeSplenic2012c?,wienandGenomicAnalysesFlowsorted2019b?
ATP6AP1 Tier 1 GEokosunRecurrentMTORC1activatingRRAGC2016a? Okosun et al
ATP6V1B2 Tier 1 GEokosunRecurrentMTORC1activatingRRAGC2016a? Okosun et al
B2M Tier 1 GE4, FEchalla-malladiCombinedGeneticInactivationa? Morin et al 5,reichelFlowSortingExome2015a?
BCL2 Tier 1 GE4, FE6 Morin et al 7,burkhardtClinicalRelevanceMolecular2022b?,sarkozyMutationalLandscapeGray2021a?
BCL6 Tier 1 GE, FE6 2,4
BCL7A Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FEbalinas-gaviraFrequentMutationsAminoterminal2020b? Krysiak et al 4,8,reichelFlowSortingExome2015a?
BIRC6 Tier 1 GE 9,sarkozyMutationalLandscapeGray2021a?
BTG1 Tier 1 GE, FEmlynarczykBTG1MutationYields2023b? 4,burkhardtClinicalRelevanceMolecular2022b?,sarkozyMutationalLandscapeGray2021a?
BTG2 Tier 1 GE4, CE10 Morin et al 2
BTK Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al albuquerqueEnhancingKnowledgeDiscovery2017a?
CARD11 Tier 1 GE4, FE11, CEzhaoExpressionPrognosticValue2016? Morin et al 11,12,yanBCRTLRSignaling2012a?
CCND3 Tier 1 GE4, FE13 Morin et al 14,15,richterRecurrentMutationID32012a?
CD83 Tier 1 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 16,17,dunsCharacterizationDLBCLPMBL2021b?
CREBBP Tier 1 GEpasqualucciInactivatingMutationsAcetyltransferase2011a?, FEpasqualucciInactivatingMutationsAcetyltransferase2011a? Pasqualucci et al 2,18,dunsCharacterizationDLBCLPMBL2021b?
CTSS Tier 1 GEbarariaCathepsinAlterationsInduce2020c? Bararia et al
DTX1 Tier 1 GE, FE19, CEmerirantaDeltex1MutationsPredict2017b? 2,3,20,rossiCodingGenomeSplenic2012c?
EBF1 Tier 1 GE 21,22,reichelFlowSortingExome2015a?
EEF1A1 Tier 1 GEhubschmannMutationalMechanismsShaping2021b?, CEgongExpressionClinicalValue2021? Hubschmann et al reichelFlowSortingExome2015a?
EP300 Tier 1 GEpasqualucciInactivatingMutationsAcetyltransferase2011a?, FEpasqualucciInactivatingMutationsAcetyltransferase2011a? Pasqualucci et al rossiCodingGenomeSplenic2012c?
EZH2 Tier 1 GEmorinSomaticMutationsAltering2010a?, FEyapSomaticMutationsEZH22011b? Morin et al 2,mottokIntegrativeGenomicAnalysis2019b?
FAS Tier 1 GE, FE23 24,spinaGeneticsNodalMarginal2016b?
FOXO1 Tier 1 GE4, FE25, CE25 Morin et al 13,dunsCharacterizationDLBCLPMBL2021b?
GNA13 Tier 1 GE4, FEmuppidiLossSignalingGa132014b? Morin et al 2,reichelFlowSortingExome2015a?
GNAI2 Tier 1 GE 8,16
HIST1H1B Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al chapuyMolecularSubtypesDiffuse2018b?,sarkozyMutationalLandscapeGray2021a?
HIST1H1C Tier 1 GE4 Morin et al 17
HIST1H1D Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 15,16
HIST1H1E Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 8,lohrDiscoveryPrioritizationSomatic2012a?,reichelFlowSortingExome2015a?
HIST1H2AC Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 16
HIST1H2AG Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 16,17,rossiCodingGenomeSplenic2012c?
HIST1H2AM Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 17,chapuyMolecularSubtypesDiffuse2018b?
HIST1H2BC Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al lohrDiscoveryPrioritizationSomatic2012a?,mottokIntegrativeGenomicAnalysis2019b?
HIST1H2BD Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H2BG Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H3B Tier 1 GE lohrDiscoveryPrioritizationSomatic2012a?,reichelFlowSortingExome2015a?
HIST1H3G Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HVCN1 Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al chapuyMolecularSubtypesDiffuse2018b?
IRF4 Tier 1 GE 4,mottokIntegrativeGenomicAnalysis2019b?
IRF8 Tier 1 GE4, FE26 Morin et al 17,mottokIntegrativeGenomicAnalysis2019b?
ITPKB Tier 1 GE reichelFlowSortingExome2015a?,schmitzGeneticsPathogenesisDiffuse2018a?
KLF2 Tier 1 GE 14,15,27
KLHL6 Tier 1 GE4, FE28 Morin et al 29
KMT2D Tier 1 GE4, FE30, CE31 Morin et al 8,14,32,rossiCodingGenomeSplenic2012c?
LTB Tier 1 GE 14,chapuyMolecularSubtypesDiffuse2018b?
MAP2K1 Tier 1 GElouissaintPediatrictypeNodalFollicular2016a? Louissaint et al 33
MEF2B Tier 1 GE4, FE34 Morin et al 32
MEF2C Tier 1 GE, FE35 36
PCLO Tier 1 GE lohrDiscoveryPrioritizationSomatic2012a?
PIM1 Tier 1 GE, CE37 burkhardtClinicalRelevanceMolecular2022b?,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciHypermutationMultipleProtooncogenes2001a?
POU2AF1 Tier 1 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al chapuyMolecularSubtypesDiffuse2018b?
POU2F2 Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FEhodsonRegulationNormalBcell2016a? Krysiak et al lohrDiscoveryPrioritizationSomatic2012a?
PTPRD Tier 1 GE spinaGeneticsNodalMarginal2016b?
RRAGC Tier 1 GE, FEortega-molinaOncogenicRagGTPase2019b? okosunRecurrentMTORC1activatingRRAGC2016a?
S1PR2 Tier 1 GE, FE38 4,muppidiLossSignalingGa132014b?
SGK1 Tier 1 GE4, FEhartmannHighlyRecurrentMutations2016b?, CE37 Morin et al dunsCharacterizationDLBCLPMBL2021b?
SMARCA4 Tier 1 GEkrysiakRecurrentSomaticMutations2017b?, FE39 Krysiak et al 9,nadeuGenomicEpigenomicInsights2020b?,richterRecurrentMutationID32012a?
SOCS1 Tier 1 GE, FEmelznerBiallelicMutationSOCS12005a? 4,wenigerMutationsTumorSuppressor2006a?
STAT6 Tier 1 GEyildizActivatingSTAT6Mutations2015c?, FEyildizActivatingSTAT6Mutations2015c? Yildiz et al ritzRecurrentMutationsSTAT62009a?
TBL1XR1 Tier 1 GE, FEventuruttiTBL1XR1MutationsDrive2020b? lohrDiscoveryPrioritizationSomatic2012a?,rossiCodingGenomeSplenic2012c?
TMSB4X Tier 1 GE 3
TNFAIP3 Tier 1 GE, FEcompagnoMutationsMultipleGenes2009a? compagnoMutationsMultipleGenes2009a?,rossiAlterationBIRC3Multiple2011a?,schmitzTNFAIP3A20Tumor2009a?
TNFRSF14 Tier 1 GEcheungAcquiredTNFRSF14Mutations2010a?, CE37 Cheung et al 4,spinaGeneticsNodalMarginal2016b?
TP53 Tier 1 GE4, FErowhTp53DeletionLineage2011? Morin et al 32,40,lohrDiscoveryPrioritizationSomatic2012a?,rossiCodingGenomeSplenic2012c?,tiacciPervasiveMutationsJAKSTAT2018b?
VMA21 Tier 1 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al

Tier 2 FL genes

49 total

Gene Summary First FL study Other entities QC result
ABL2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
ACTG1 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al 14,spinaGeneticsNodalMarginal2016b?
ATP6V1A Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
BCL10 Tier 2 GErussler-germainMutationsAssociatedProgression2023b?, FE41 Russler et al 4,spinaGeneticsNodalMarginal2016b?
CD70 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 4
CD79B Tier 2 GE, FE42 4,17
CDC42BPB Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al spinaGeneticsNodalMarginal2016b?
CILP Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
CPNE8 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
CXCR4 Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 17,43
CYP2A6 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
DDX3X Tier 2 GE, FE44, CEkizhakeyilDDX3XLossAdverse2021? 9,13,mottokIntegrativeGenomicAnalysis2019b?
DHX15 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
DUSP2 Tier 2 GE dunsCharacterizationDLBCLPMBL2021b?,lohrDiscoveryPrioritizationSomatic2012a?
EGR1 Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al reichelFlowSortingExome2015a?,rossiCodingGenomeSplenic2012c?
FZR1 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
GBP7 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
GRM6 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
HIST1H2BM Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al
HIST1H3I Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 17
HLA-B Tier 2 GE lohrDiscoveryPrioritizationSomatic2012a?,wienandGenomicAnalysesFlowsorted2019b?
HNRNPD Tier 2 GE 9
IGLL5 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 14,17,chapuyMolecularSubtypesDiffuse2018b?
JUP Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
KIR3DL1 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
LAPTM5 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
MAGEC1 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
MAP7D1 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
MGEA5 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
MKI67 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 13
MYC Tier 2 GE, FE45, CE46 15,47,dunsCharacterizationDLBCLPMBL2021b?,pasqualucciHypermutationMultipleProtooncogenes2001a?
MYCBP2 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
MYD88 Tier 2 GE, FEngoOncogenicallyActiveMYD882011a?, CE37 ngoOncogenicallyActiveMYD882011a?,yanBCRTLRSignaling2012a?
NFKBIA Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 48,wienandGenomicAnalysesFlowsorted2019b?
OR8H2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
P2RY8 Tier 2 GE, FEmuppidiLossSignalingGa132014b? lohrDiscoveryPrioritizationSomatic2012a?,muppidiLossSignalingGa132014b?
PDS5B Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al 16
PPP4C Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
PRKDC Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al schmitzGeneticsPathogenesisDiffuse2018a?
PZP Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
RBM6 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
SHROOM3 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
SRRM2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al 16
STAB2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
TMEM30A Tier 2 GE4, FEennishiTMEM30ALossoffunctionMutations2020b?, CEennishiTMEM30ALossoffunctionMutations2020b? Morin et al
TPP1 Tier 2 GEhubschmannMutationalMechanismsShaping2021b? Hubschmann et al
XIRP2 Tier 2 GErussler-germainMutationsAssociatedProgression2023b? Russler et al
ZC3H12A Tier 2 GE chapuyMolecularSubtypesDiffuse2018b?
ZNF608 Tier 2 GEkrysiakRecurrentSomaticMutations2017b? Krysiak et al 16

Tier 3 FL genes

0 total

Gene Summary First FL study Other entities QC result

References

1.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell. 2024 Apr 8;42(4):583–604.e11.
2.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325. PMCID: PMC3674561
3.
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:1398–1403. PMCID: PMC3557051
4.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298–303. PMCID: PMC3210554
5.
Pararajalingam P, Coyle KM, Arthur SE, Thomas N, Alcaide M, Meissner B, Boyle M, Qureshi Q, Grande BM, Rushton C, Slack GW, Mungall AJ, Tam CS, Agarwal R, Dawson SJ, Lenz G, Balasubramanian S, Gascoyne RD, Steidl C, Connors J, Villa D, Audas TE, Marra MA, Johnson NA, Scott DW, Morin RD. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020 Jul 30;136(5):572–584. PMCID: PMC7440974
6.
Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabanian H, Pasqualucci L, Dalla-Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature. 2022 Jul;607(7920):808–815. PMCID: PMC9583699
7.
Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin’s lymphomas. Blood. 1992 Jan 1;79(1):229–237.
8.
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324. PMCID: PMC6428665
9.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017 Oct;171(2):481–494.e15. PMCID: PMC5659841
10.
Guo D, Hong L, Ji H, Jiang Y, Lu L, Wang X, Huang H. The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. J Inflamm Res. 2022;15:1757–1769. PMCID: PMC8923029
11.
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008 Mar;319(5870):1676–1679.
12.
Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, Galazka K, Dlugosz-Danecka M, Machaczka M, Zhang H, Peng R, Morin RD, Rosenquist R, Sander B, Pan-Hammarström Q. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016 Jun 21;7(25):38180–38190. PMCID: PMC5122381
13.
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867
14.
Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF, Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW, Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A, Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020 Jan;34(1):151–166.
15.
Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles G, Traverse-Glehen A. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
16.
Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992
17.
Panea R, Love C, Shingleton JR, Reddy A, Bailey J, Moormann A, Otieno J, Ong’echa J, Oduor C, Schroêder K, Masalu N, Chao N, Agajanian M, Major M, Fedoriw Y, Richards K, Rymkiewicz G, Miles R, Alobeid B, Bhagat G, Flowers C, Ondrejka S, Hsi E, Choi W, Au-Yeung R, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig M, Waldrop A, Dave T, Thakkar D, Sahay H, Li G, Palus B, Seshadri V, Kim S, Gascoyne R, Levy S, Mukhopadhyay M, Dunson D, Dave S. The whole genome landscape of Burkitt lymphoma subtypes. Blood. 2019;
18.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8(12):e83244. PMCID: PMC3862727
19.
de Miranda NFCC, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, Lisboa S, Enblad G, Teixeira MR, Zeng Y, Peng R, Pan-Hammarström Q. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014 Oct 16;124(16):2544–2553. PMCID: PMC4199956
20.
Gomez F, Fisk B, McMichael JF, Mosior M, Foltz JA, Skidmore ZL, Duncavage EJ, Miller CA, Abel H, Li YS, Russler-Germain DA, Krysiak K, Watkins MP, Ramirez CA, Schmidt A, Martins Rodrigues F, Trani L, Khanna A, Wagner JA, Fulton RS, Fronick CC, O’Laughlin MD, Schappe T, Cashen AF, Mehta-Shah N, Kahl BS, Walker J, Bartlett NL, Griffith M, Fehniger TA, Griffith OL. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma. Cancer Res Commun. 2023 Nov 15;3(11):2312–2330. PMCID: PMC10648575
21.
Bohle V, Döring C, Hansmann M-L, Küppers R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia. 2013 Mar;27(3):671–679.
22.
Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, Barta S, Bartlett NL, Bethony J, Bhatia K, Bowen J, Bryan AC, Cesarman E, Casper C, Chadburn A, Cruz M, Dittmer DP, Dyer MA, Farinha P, Gastier-Foster JM, Gerrie AS, Grande BM, Greiner T, Griner NB, Gross TG, Harris NL, Irvin JD, Jaffe ES, Henry D, Huppi R, Leal FE, Lee MS, Martin JP, Martin MR, Mbulaiteye SM, Mitsuyasu R, Morris V, Mullighan CG, Mungall AJ, Mungall K, Mutyaba I, Nokta M, Namirembe C, Noy A, Ogwang MD, Omoding A, Orem J, Ott G, Petrello H, Pittaluga S, Phelan JD, Ramos JC, Ratner L, Reynolds SJ, Rubinstein PG, Sissolak G, Slack G, Soudi S, Swerdlow SH, Traverse-Glehen A, Wilson WH, Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin RD. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023 Feb 23;141(8):904–916. PMCID: PMC10023728
23.
Seeberger H, Starostik P, Schwarz S, Knörr C, Kalla J, Ott G, Müller-Hermelink HK, Greiner A. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab Invest. 2001 Jul;81(7):977–986.
24.
Scholl V, Stefanoff CG, Hassan R, Spector N, Renault IZ. Mutations within the 5’ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2007 May;48(5):957–963.
25.
Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJM, Mungall AJ, Zhao Y, Schein J, Steidl C, Connors JM, Gascoyne RD, Marra MA. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–3674. PMCID: PMC3643765
26.
Qiu Z, Khalife J, Ethiraj P, Jaafar C, Lin AP, Holder KN, Ritter JP, Chiou L, Huelgas-Morales G, Aslam S, Zhang Z, Liu Z, Arya S, Gupta YK, Dahia PLM, Aguiar RCT. IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes. Sci Adv. 2024 Jul 12;10(28):eadk2091. PMCID: PMC11244530
27.
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul 31;43(9):830–837. PMCID: PMC3297422
28.
Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandaric L, Karjalainen-Lindsberg ML, Hyytiainen M, Varjosalo M, Myklebust JH, Leppa S. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma. Blood Cancer Discov. 2024 Apr 17;
29.
Ganapathi KA, Jobanputra V, Iwamoto F, Jain P, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G. The genetic landscape of dural marginal zone lymphomas. Oncotarget. Impact Journals; 2016 May 27;7(28):43052–43061.
30.
Li J, Chin CR, Ying HY, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu CS, Jiang Y, Eagles J, Passerini V, Tang Z, Rivas MA, Weigert O, Pugh TJ, Chadburn A, Steidl C, Scott DW, Roeder RG, Mason CE, Zappasodi R, Béguelin W, Melnick AM. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024 Apr 3;15(1):2879. PMCID: PMC10991284
31.
Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Rys RN, Jain M, Shepherd L, Marra MA, Kuruvilla J, Crump M, Mann K, Assouline S, Connors JM, Steidl C, Cragg MS, Scott DW, Johnson NA, Morin RD. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020 Jul 14;4(13):2886–2898. PMCID: PMC7362366
32.
Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Croce LD, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. PNAS. 2013;110(45):18250–18255.
33.
Shin SY, Lee ST, Kim HJ, Ki CS, Jung CW, Kim JW, Kim SH. BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. Ann Lab Med. 2015 Mar;35(2):257–259. PMCID: PMC4330180
34.
Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC, Bansal M, Califano A, Pasqualucci L, Basso K, Dalla-Favera R. MEF2B Mutations Lead to De-Regulated Expression of the BCL6 Oncogene in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Blood. 120.
35.
Jingjing Z, Lei M, Jie Z, Sha C, Yapeng H, Weimin Z, Chunluan Y. A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression. Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1549–1558.
36.
Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018 Oct 1;9(1):4001. PMCID: PMC6167379
37.
Guo B, Huang Y, Duan Y, Liao C, Cen H. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. Cancer Med. 2022 Mar;11(5):1281–1291. PMCID: PMC8894717
38.
Flori M, Schmid CA, Sumrall ET, Tzankov A, Law CW, Robinson MD, Müller A. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood. 2016 Mar 17;127(11):1438–1448.
39.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024 Apr 8;42(4):605–622.e11. PMCID: PMC11003852
40.
Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A, Woessmann W. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt’s lymphoma in children. Leukemia. 2004 Mar;18(3):584–588.
41.
Xia M, David L, Teater M, Gutierrez J, Wang X, Meydan C, Lytle A, Slack GW, Scott DW, Morin RD, Onder O, Elenitoba-Johnson KSJ, Zamponi N, Cerchietti L, Lu T, Philippar U, Fontan L, Wu H, Melnick AM. BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer Discov. 2022 Aug 5;12(8):1922–1941. PMCID: PMC9357155
42.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan;463(7277):88–92. PMCID: PMC2845535
43.
Khodabakhshi AH, Morin RD, Fejes AP, Mungall AJ, Mungall KL, Bolger-Munro M, Johnson NA, Connors JM, Gascoyne RD, Marra MA, Birol I, Jones SJM. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319. PMCID: PMC3717795
44.
Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Molecular Cell. 2021;
45.
Giallongo A, Appella E, Ricciardi R, Rovera G, Croce CM. Identification of the c-myc oncogene product in normal and malignant B cells. Science. 1983 Oct 28;222(4622):430–432.
46.
Christie L, Kernohan N, Levison D, Sales M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D, Goodlad J. C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk Lymphoma. 2008 Mar;49(3):470–476.
47.
Johnston JM, Carroll WL. C-myc hypermutation in Burkitt’s lymphoma. Leuk Lymphoma. 1992 Dec;8(6):431–439.
48.
Thomas RK, Wickenhauser C, Tawadros S, Diehl V, Küppers R, Wolf J, Schmitz R. Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma. Br J Haematol. 2004 Jul;126(1):50–54.